These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 22459389)

  • 1. CRP and suPAR are differently related to anthropometry and subclinical organ damage.
    Lyngbæk S; Sehestedt T; Marott JL; Hansen TW; Olsen MH; Andersen O; Linneberg A; Madsbad S; Haugaard SB; Eugen-Olsen J; Jeppesen J
    Int J Cardiol; 2013 Aug; 167(3):781-5. PubMed ID: 22459389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble urokinase plasminogen activator receptor is associated with subclinical organ damage and cardiovascular events.
    Sehestedt T; Lyngbæk S; Eugen-Olsen J; Jeppesen J; Andersen O; Hansen TW; Linneberg A; Jørgensen T; Haugaard SB; Olsen MH
    Atherosclerosis; 2011 May; 216(1):237-43. PubMed ID: 21354571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular risk prediction in the general population with use of suPAR, CRP, and Framingham Risk Score.
    Lyngbæk S; Marott JL; Sehestedt T; Hansen TW; Olsen MH; Andersen O; Linneberg A; Haugaard SB; Eugen-Olsen J; Hansen PR; Jeppesen J
    Int J Cardiol; 2013 Sep; 167(6):2904-11. PubMed ID: 22909410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus.
    Enocsson H; Wetterö J; Skogh T; Sjöwall C
    Transl Res; 2013 Nov; 162(5):287-96. PubMed ID: 23916811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble urokinase plasminogen activator receptor is in contrast to high-sensitive C-reactive-protein associated with coronary artery calcifications in healthy middle-aged subjects.
    Sørensen MH; Gerke O; Eugen-Olsen J; Munkholm H; Lambrechtsen J; Sand NP; Mickley H; Rasmussen LM; Olsen MH; Diederichsen A
    Atherosclerosis; 2014 Nov; 237(1):60-6. PubMed ID: 25222341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble urokinase plasminogen activator receptor in plasma is associated with incidence of CVD. Results from the Malmö Diet and Cancer Study.
    Persson M; Engström G; Björkbacka H; Hedblad B
    Atherosclerosis; 2012 Feb; 220(2):502-5. PubMed ID: 22119508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population.
    Eugen-Olsen J; Andersen O; Linneberg A; Ladelund S; Hansen TW; Langkilde A; Petersen J; Pielak T; Møller LN; Jeppesen J; Lyngbaek S; Fenger M; Olsen MH; Hildebrandt PR; Borch-Johnsen K; Jørgensen T; Haugaard SB
    J Intern Med; 2010 Sep; 268(3):296-308. PubMed ID: 20561148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble urokinase plasminogen activator receptor levels are elevated and associated with complications in patients with type 1 diabetes.
    Theilade S; Lyngbaek S; Hansen TW; Eugen-Olsen J; Fenger M; Rossing P; Jeppesen JL
    J Intern Med; 2015 Mar; 277(3):362-371. PubMed ID: 24830873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Usefulness of soluble urokinase plasminogen activator receptor to predict repeat myocardial infarction and mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous intervention.
    Lyngbæk S; Marott JL; Møller DV; Christiansen M; Iversen KK; Clemmensen PM; Eugen-Olsen J; Jeppesen JL; Hansen PR
    Am J Cardiol; 2012 Dec; 110(12):1756-63. PubMed ID: 22981263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The immune marker soluble urokinase plasminogen activator receptor is associated with new-onset diabetes in non-smoking women and men.
    Haugaard SB; Andersen O; Hansen TW; Eugen-Olsen J; Linneberg A; Madsbad S; Olsen MH; Jørgensen T; Borch-Johnsen K; Jeppesen J
    Diabet Med; 2012 Apr; 29(4):479-87. PubMed ID: 22050462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cadmium exposure is associated with soluble urokinase plasminogen activator receptor, a circulating marker of inflammation and future cardiovascular disease.
    Fagerberg B; Borné Y; Barregard L; Sallsten G; Forsgard N; Hedblad B; Persson M; Engström G
    Environ Res; 2017 Jan; 152():185-191. PubMed ID: 27792942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma soluble urokinase-type plasminogen activator receptor level is independently associated with coronary microvascular function in patients with non-obstructive coronary artery disease.
    Mekonnen G; Corban MT; Hung OY; Eshtehardi P; Eapen DJ; Al-Kassem H; Rasoul-Arzrumly E; Gogas BD; McDaniel MC; Pielak T; Thorball CW; Sperling L; Quyyumi AA; Samady H
    Atherosclerosis; 2015 Mar; 239(1):55-60. PubMed ID: 25574858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble urokinase-type plasminogen activator receptor forms in plasma as markers of atherosclerotic plaque vulnerability.
    Olson FJ; Thurison T; Ryndel M; Høyer-Hansen G; Fagerberg B
    Clin Biochem; 2010 Jan; 43(1-2):124-30. PubMed ID: 19822140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The association of plasma C-reactive protein levels with anthropometric and lipid parameters in elderly Taiwanese.
    Tsai HJ; Tsai AC
    Asia Pac J Clin Nutr; 2008; 17(4):651-6. PubMed ID: 19114404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluble urokinase plasminogen activator receptor suPAR as a marker for inflammation in pediatric inflammatory bowel disease.
    Kolho KL; Valtonen E; Rintamäki H; Savilahti E
    Scand J Gastroenterol; 2012 Sep; 47(8-9):951-5. PubMed ID: 22746351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma soluble urokinase plasminogen activator receptor (suPAR) levels in systemic lupus erythematosus.
    Toldi G; Szalay B; Bekő G; Bocskai M; Deák M; Kovács L; Vásárhelyi B; Balog A
    Biomarkers; 2012 Dec; 17(8):758-63. PubMed ID: 23033975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of obesity with inflammation in chronic kidney disease: a cross-sectional study.
    Ramkumar N; Cheung AK; Pappas LM; Roberts WL; Beddhu S
    J Ren Nutr; 2004 Oct; 14(4):201-7. PubMed ID: 15483779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble urokinase plasminogen activator receptor is compartmentally regulated in decompensated cirrhosis and indicates immune activation and short-term mortality.
    Zimmermann HW; Reuken PA; Koch A; Bartneck M; Adams DH; Trautwein C; Stallmach A; Tacke F; Bruns T
    J Intern Med; 2013 Jul; 274(1):86-100. PubMed ID: 23432143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble urokinase plasminogen activator receptor is associated with inflammation in the vulnerable human atherosclerotic plaque.
    Edsfeldt A; Nitulescu M; Grufman H; Grönberg C; Persson A; Nilsson M; Persson M; Björkbacka H; Gonçalves I
    Stroke; 2012 Dec; 43(12):3305-12. PubMed ID: 23150653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibroblast growth factor 23, hepatocyte growth factor, interleukin-6, high-sensitivity C-reactive protein and soluble urokinase plasminogen activator receptor. Inflammation markers in chronic haemodialysis patients?
    Almroth G; Lönn J; Uhlin F; Nayeri F; Brudin L; Andersson B; Hahn-Zoric M
    Scand J Immunol; 2013 Sep; 78(3):285-90. PubMed ID: 23721058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.